Potential Role of N-Acetylcysteine in the Management of Substance Use Disorders
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
There is a clear and pressing need to expand pharmacotherapy options for substance use disorders (SUDs) in order to improve sustained abstinence outcomes. Preclinical literature has demonstrated the role of glutamate in addiction, suggesting that new targets for pharmacotherapy should focus on the restoration of glutamatergic function. Glutamatergic agents for SUDs may span multiple addictive behaviors and help demonstrate potentially overlapping mechanisms in addiction. The current review will focus specifically on N-acetylcysteine (NAC), a safe and well-tolerated glutamatergic agent, as a promising potential pharmacotherapy for the treatment of SUDs across several substances of abuse. Building on recently published reviews of the clinical efficacy of NAC across a broad range of conditions, this review will more specifically discuss NAC as a pharmacotherapy for SUDs, devoting particular attention to the safety and tolerability profile of NAC, the wealth of preclinical evidence that has demonstrated the role of glutamate dysregulation in addiction, and the limited but growing clinical literature that has assessed the efficacy of NAC across multiple substances of abuse. Preliminary clinical studies show the promise of NAC in terms of safety, tolerability, and potential efficacy for promoting abstinence from cocaine, nicotine, and cannabis. Results from randomized clinical trials have been mixed, but several mechanistic and methodological factors are discussed to refine the use of NAC in promoting abstinence and relapse prevention across several substances of abuse. Further preclinical and clinical investigation into the use of NAC for SUDs will be vital in addressing current deficits in the treatment of SUDs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y., & Patra, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60746-7 · Cited by 3,870
Structural basis of long-term potentiation in single dendritic spines
Matsuzaki, M., Honkura, N., Ellis-Davies, G. C. R., & Kasai, H. (2004) · Nature · doi:10.1038/nature02617 · Cited by 2,483 · cited 1×
“Since presynaptic and non-synaptic glutamate release regulates synaptic plasticity in both primary cell cultures and in vivo [63, 64], the LTP-like changes may arise from the reinstatement-associated increase in glutamate release and overflow [44, 45, 65].”
BackgroundThe role of the basal ganglia in habit formation
Yin, H. H., & Knowlton, B. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1919 · Cited by 2,402
Clinical Practice Guideline: Otitis Media with Effusion (Update)
Rosenfeld, R. M., Shin, J. J., Schwartz, S. R., Coggins, R., Gagnon, L., Hackell, J. M., Hoelting, D., Hunter, L. L., Kummer, A. W., Payne, S. C., et al. (2016) · Otolaryngology–Head and Neck Surgery · doi:10.1177/0194599815623467 · Cited by 2,006
Gonzales, D. (2006) · JAMA · doi:10.1001/jama.296.1.47 · Cited by 1,361 · cited 2×
“However, even with varenicline, arguably the most efficacious smoking cessation pharmacotherapy, abstinence rates after 12 weeks of treatment are still only approximately 40 % [12–14].”
BackgroundThe glutamate homeostasis hypothesis of addiction
Kalivas, P. W. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2515 · Cited by 1,350 · cited 1×
“recreational use) arises from an impaired ability of this circuit to successfully process negative environmental contingencies, leading to decreased capacity to inhibit prepotent drugassociated responses [41, 69].”
BackgroundSelf-citationPharmacological interventions for smoking cessation: an overview and network meta-analysis
Cahill, K., Stevens, S., Perera, R., & Lancaster, T. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009329.pub2 · Cited by 1,243 · cited 1×
“Within the smoking cessation literature, nicotine replacement therapy (NRT), bupropion, and varenicline have been shown to increase the odds of quitting smoking by two to threefold compared with placebo [11].”
BackgroundDole, V. P. (1965) · JAMA · doi:10.1001/jama.1965.03090080008002 · Cited by 1,240 · cited 1×
“methadone maintenance) were demonstrated to be effective in improving treatment outcomes [7], thus representing a pivotal moment in the treatment of SUDs.”
BackgroundEfficacy of Oral N-Acetylcysteine in the Treatment of Acetaminophen Overdose
Smilkstein, M. J., Knapp, G. L., Kulig, K. W., & Rumack, B. H. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812153192401 · Cited by 1,102
Cited by
Everitt, B. J. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12644 · Cited by 318
A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults.
Gray, K. M., Sonne, S. C., McClure, E. A., Ghitza, U. E., Matthews, A. G., McRae-Clark, A. L., Carroll, K. M., Potter, J. S., Wiest, K., Mooney, L. J., et al. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.04.020 · Cited by 157
“2.3 General Procedures Details of study design have been described previously (McClure et al., 2014).”
BackgroundMethodSelf-citationPharmacological Treatment of Youth Substance Use Disorders
Squeglia, L. M., Fadus, M. C., McClure, E. A., Tomko, R. L., & Gray, K. M. (2019) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2019.0009 · Cited by 79
Self-citationCullen, K. R., Schreiner, M. W., Klimes-Dougan, B., Eberly, L. E., LaRiviere, L. L., Lim, K. O., Camchong, J., & Mueller, B. A. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109778 · Cited by 34
Advances and challenges in pharmacotherapeutics for amphetamine-type stimulants addiction
Cao, D.-N., Shi, J.-J., Hao, W., Wu, N., & Li, J. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.03.040 · Cited by 34
Metadata
- Authors
- McClure, E. A., Gipson, C. D., Malcolm, R. J., Kalivas, P. W., & Gray, K. M.
- Venue
- CNS Drugs
- Published
- 2014-01-18
- Volume
- 28
- Issue
- 2
- Pages
- 95-106
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W1971398808
- Cited by
- 193
- References
- 27
- FWCI
- 10.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potential Role of N-Acetylcysteine in the Management of Substance Use Disorders. https://app.cochat.ai/papers/10.1007/s40263-014-0142-x
- The paper
- McClure, E. A., Gipson, C. D., Malcolm, R. J., Kalivas, P. W., & Gray, K. M. (2014). Potential Role of N-Acetylcysteine in the Management of Substance Use Disorders. CNS Drugs. https://doi.org/10.1007/s40263-014-0142-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.